Article

4th Dose COVID mRNA Vaccines’ Immunogenicity & Efficacy Against Omicron VOC

2022-02-15

Abstract excerpt

<h4>BACKGROUND</h4> Following the emergence of the Omicron variant of concern, we investigated immunogenicity, efficacy and safety of BNT162b2 or mRNA1273 fourth dose in an open-label, clinical intervention trial. <h4>METHODS</h4> Primary end-points were safety and immunogenicity and secondary end-points were vaccine efficacy in preventing SARS-CoV-2 infections and COVID-19 symptomatic disease. The two interventio...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 33e79a75-e867-56c0-8f7d-18f1d812ec48
DOI: 10.1101/2022.02.15.22270948

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

4th Dose COVID mRNA Vaccines’ Immunogenicity & Efficacy Against Omicron VOCDOI 10.1101/2022.02.15.22270948Read

Immune Response and Clinical Outcomes of BNT162b2 and mRNA1273 Fourth Dose COVID-19 Vaccines; Three Months Follow-upSemantic proximity Read

A Bivalent Omicron-containing Booster Vaccine Against Covid-19Semantic proximity Read

Antibody Response of Heterologous vs Homologous mRNA Vaccine Boosters Against the SARS-CoV-2 Omicron Variant: Interim Results from the PRIBIVAC Study, A Randomized Clinical TrialSemantic proximity Read

Interim Safety and Immunogenicity of COVID-19 Omicron-BA.1 Variant-Containing Vaccine in ChildrenSemantic proximity Read

mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variantSemantic proximity Read

Divergent SARS CoV-2 Omicron-specific T- and B-cell responses in COVID-19 vaccine recipientsSemantic proximity Read

Comprehensive antibody profiling of mRNA vaccination in childrenSemantic proximity Read

mRNA-1273 Vaccine-elicited Neutralization of SARS-CoV-2 Omicron in Adolescents and ChildrenSemantic proximity Read

Serum Neutralizing Activity of mRNA-1273 Against the SARS-CoV-2 B.1.1.529 (Omicron) Variant: A Preliminary ReportSemantic proximity Read

SARS-CoV-2 Omicron Variant Infection of Individuals with High Titer Neutralizing Antibodies Post-3<sup>rd</sup> mRNA Vaccine DoseSemantic proximity Read

Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac VaccinationSemantic proximity Read

Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19Semantic proximity Read